As GLP-1 receptor agonists move into wider use for diabetes and weight management, many primary care clinicians are discovering that prescribing the medication is only half the challenge. The other ...

Research collected by University of Guelph post doctoral scholar Megan Ross as part of her recent PhD work from the Atlantic ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.

Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.

Parents in Wiltshire might want to put the chocolates on a high shelf and keep an eye on the fizzy drinks this Christmas, ...

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

A major review in Frontiers in Science highlights how tackling unsustainable food systems—reflected by our changing food ...

A selective androgen receptor modulator combined with a GLP-1 may induce weight loss for older adults with obesity while ...

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

A major review in Frontiers in Science highlights how tackling unsustainable food systems—reflected by our changing food ...